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Objective: Adenocarcinoma of the esophagus i generally attributed to the 
neoplastic transformation of intestinal metaplastic lesions (Barrett's 
esophagus). On the basis of our preliminary data that showed signifi- 
cant acidic fibroblast growth factor mRNA and protein expression in 
adenocarcinoma of the esophagus, we studied expression of fibroblast 
growth factor in esophageal denocarcinoma and its precursor lesions, 
intestinal metaplasia, low-grade dysplasia, and high-grade dysplasia. 
Fibroblast growth factor belongs to a family of polypeptides that are 
involved in differentiation and cellular proliferation. Methods: We 
examined 30 esophagectomy specimens that were resected for adenocar- 
cinoma (n = 27) and high-grade dysplasia (n = 3). After confirmation of 
the diagnosis by routine light microscopy, the index lesions (invasive 
carcinomas) and adjoining Barrett's mucosa were evaluated with a 
monoclonal antibody against human acidic fibroblast growth factor. The 
results are expressed with the use of an immunoreactive score that 
allows distinction between weak, moderate, and strong immunoreactiv- 
ity. Results: Adenocarcinoma demonstrated a moderate-to-strong mean 
immunoreactive score of 8. In contrast, high-grade dysplasia demon- 
strated a weak-to-moderate mean score of 4.5, which was significantly 
different (p < 0.05). Intestinal metaplasia nd low-grade dysplasia 
displayed even weaker expression of fibroblast growth factor, with a 
negligible immunoreactive score less than 1 (p < 0.005). Seventy-five 
percent of evaluable cases demonstrated an increasing degree of fibro- 
blast growth factor expression in the spectrum of lesions ranging from 
metaplasia to dysplasia nd carcinoma. Conclusions: These data indicate 
that in patients with adenocarcinoma arising in association with 
Barrett's esophagus, fibroblast growth factor is generally sequentially 
accumulated in the progression from metaplasia to neoplasia. This 
progression may affect future investigation into the role of fibroblast 
growth factors in tumorigenesis and, possibly, the application of fibro- 
blast growth factor immunohistochemistry o diagnosis. (J Thorac 
Cardiovasc Surg 1997;114:838-43) 
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a arrett's esophagus poses numerous diagnostic 
and therapeutic difficulties. Of compelling inter- 
est is the association of intestinal metaplasia nd 
superimposed dysplasia with esophageal adenocar- 
cinoma. These putative precursors of carcinoma 
may place a patient at risk for the development of 
invasive adenocarcinoma. They also provoke re- 
search interest because of the opportunity they 
provide to examine sequential changes in onco- 
genes, tumor suppressor genes, and cell cycle regu- 
lators, as well as adhesion molecules and angiogen- 
esis factor expression that are associated with the 
development of invasive carcinoma. In this study we 
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Table I. Staining 
Score Description 
1+ 
2+ 
3+ 
4+ 
1-3 
4-8 
9-12 
13-16 
Staining intensity 
Weak, uniform, brown, cytoplasmic coloration just 
beyond the level of any background staining 
Moderate, uniform, brown, cytoplasmic coloration 
Strong, uniform, brown, cytoplasmic staining 
The darkest uniform, brown, cytoplasmic staining 
Staining distribution 
1%-25% reactive cells 
26%-50% reactive cells 
51%-75% reactive cells 
76%-100% reactive cells 
Immunoreactive scores* 
Weak expression 
Moderate xpression 
Strong expression 
Very strong expression 
*Computed by multiplying staining intensity by staining distribution. 
present data concerning acidic fibroblast growth 
factor (FGF-1), which belongs to a family of 
polypeptides involved in differentiation and cellular 
proliferation. 1 
Although the data linking FGF-1 to malignant 
neoplasms are not extensive, some of its reported 
biologic functions are potentially related to tumor 
progression and invasion. FGFs are mitogenic, pro- 
mote angiogenesis, and play an important role in 
tissue repair, including fibrosis. 2' 3 FGF-1 binding to 
its high-affinity cytoplasmic membrane receptor pro- 
motes cellular proliferation. 2 Therefore FGF-1 ex- 
pression may be indicative of autocrine growth in 
tumors that express uch receptors. 4 Angiogenesis 
has been shown to be important in the maintenance 
of invasive tumor growth and has been correlated 
with prognosis in numerous organ systems, -16 It is 
conceivable that the function of FGF-1 in tissue 
repair may also apply to the interaction between 
invasive tumors and the extracellular matrix. FGF-1 
expression has been documented in transitional cell 
carcinoma of the urinary bladder, 17 pancreatic duc- 
tal adenocarcinoma, is central nervous system glio- 
mas, 19 thyroid carcinomas, 2° head and neck tu- 
mors, 21 renal adenocarcinomas, ~9 and in chronic 
pancreatitis. 2z It has been suggested that FGF-1 
expression is correlated with advanced tumor stage 
and may adversely affect survival. 17' is 
We have previously shown that FGF mRNA and 
protein are both highly expressed in esophageal 
adenocarcinoma. 23 In the present study we evalu- 
ated the hypothesis that FGF-1 expression is ac- 
Table II. Summary of FGF-1 reactivity 
Positive Negative Percentage of 
No. No. positive cases Average IRS 
IM 6 11 35 <1 
LGD 3 10 23 < 1 
HGD 12 6 67 4.5 
CA 24 3 89 8.0 
IM,, Intestinal metaplasia; LGD, low-grade dysplasia; HGD, high-grade 
dysplasia: CA, infiltrating adenocarcinoma. 
quired sequentially in the metaplasia-dysplasia-car- 
cinoma sequence. 
Materials and methods 
Case selection and slide review. We reviewed 27 ran- 
domly selected esophagectomy specimens that contained 
invasive adenoearcinoma and three additional esophagec- 
tomy specimens that contained high-grade dysplasia oc- 
curring in the setting of intestinal (Barrett's) metaplasia. 
The reported diagnoses were confirmed on review of 
sections tained with hematoxylin and eosin. The criteria 
of Lewin and Appelman 24 to distinguish the following 
entities were used: gastric metaplasia, intestinal metapla- 
sia, dysplasia, and infiltrating adenocarcinoma. 
Immunohistochemistry. Formalin-fixed paratfin-embed- 
ded sections were selected for immunoperoxidase staining 
on the basis of the presence of invasive adenocarcinoma and, 
if present, intestinal metaplasia, low-grade dysplasia, and 
high-grade dysplasia. The tissue was incubated with a mono- 
clonal antibody against human FGF-1 (Upstate Biotechnol- 
ogy Inc., Lake Placid, N.Y.) at an antibody dilution of 1:100. 
We used a biotinylated antimouse immunoglobulin IgG 
secondary antibody and streptavidin-peroxidase complex. 
Diaminobenzidine t trahydrochloride was used as the sub- 
strate. Full-thickness sections of stomach wall, taken from 
the gastric fundus, were used as positive and negative control 
specimens. Negative control specimens were incubated with 
horse serum instead of with the primary antibody. 
Interpretation. On the basis of the pattern and inten- 
sity of reactive cells in control tissue, we assigned an 
intensity score (0 to 4+) and a distribution score (estimat- 
ed percentage of reactive cells) to describe staining of 
study cases. The criteria for scoring staining intensity 
follow: 1+, uniform brown cytoplasmic coloration that is 
just beyond the level of any background staining, if 
present; 2+, moderate, uniform brown cytoplasmic ol- 
oration; 3+, strong, uniform brown cytoplasmic colora- 
tion; 4+, the darkest uniform brown cytoplasmic olora- 
tion identified. An immunoreactive score ORS), modified 
from the German IRSy was computed to account for 
both the distribution and intensity of staining and the 
classification of staining as weak, moderate, strong, or 
very strong. To calculate the IRS, we assigned the follow- 
ing points for staining distribution: 1, 1% to 25%; 2, 26% 
to 50%; 3, 51% to 75%; 4, 76% to 100%. These points 
were then multiplied by the staining intensity score, for a 
range of potential IRSs from 0 to 16. Weak staining was 
defined as an IRS that ranged from 1 to 3; moderate 
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Fig. I. FGF-1 expression i  Barrett's esophagus and esophageal denocarcinoma. A, Intestinal metapla- 
sia: Metaplastic mucosa, which includes intestinal-type goblet cells, does not express FGF-1. B, Low-grade 
dysplasia: A subpopulation of dysplastic glands demonstrate v ry weak (light gray) cytoplasmic coloration 
with the FGF-1 monoclonal antibody. C, High-grade dysplasia: All the dysplastic glands demonstrate 
moderate-to-strong (dark gray) cytoplasmic coloration with the FGF-1 monoclonal ntibody. D, Adeno- 
carcinoma: This jagged, infiltrating nest of poorly differentiated a enocarcinoma strongly expresses FGF-1. 
Note the dark-gray cytoplasmic coloration. 
staining was 4 to 8, strong staining was 9 to 12, and very 
strong staining was 13 to 16 (Table I). 
Results 
Histology. Twenty-seven esophagectomy speci- 
mens were found to contain infiltrating adenocarci- 
noma and three specimens demonstrated high- 
grade dysplasia, occurring in the background of 
intestinal metaplasia. Twenty-two f the infiltrating 
carcinomas contained intestinal metaplastic or dys- 
plastic epithelium (or both) in the esophagectomy 
specimen. 
Immunohistochemistry 
Controls. Seven of 17 control gastric fundic mu- 
cosae demonstrated diffuse, 1 to 2+ intensity stain- 
ing of parietal cell cytoplasm (IRS = 4 to 8). The 
foveolar (surface) epithelial cells were uniformly 
negative with the anti-FGF-1 antibody ORS = 0). 
When squamous mucosa was present for immuno- 
histochemical evaluation, we identified diffuse, 1 + 
diffuse cytoplasmic staining (IRS = 1 to 4). Rare 
examples demonstrated scattered, weakly reactive 
nuclei. Ten cases did not demonstrate significant 
staining of control gastric fundic mucosa. The mus- 
cularis propria and endothelium showed iffuse, 1 to 
2+ cytoplasmic staining (IRS = 4 to 8). 
Adenocarcinoma. 1RSs ranged from 0 to 12 
(mean IRS = 8.0, moderate staining bordering on 
strong staining). Twenty-four of 27 infiltrating ade- 
nocarcinomas reviewed contained significant num- 
bers of tumor cells reactive with the anti-FGF-1 
antibody. On average, FGF-1 reactive carcinomas 
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were moderately to strongly reactive (mean IRS = 
8.5). All but one reactive case demonstrated mod- 
erate or strong FGF-1 reactivity; 15 of the adeno- 
carcinomas tudied (56%) were strongly reactive 
with anti-FGF-1, eight were moderately reactive, 
and one was weakly reactive (Table II, Fig. 1). Many 
of the tumors demonstrated a range of staining 
intensity; the average staining intensity was consid- 
ered when calculating the IRS. 
High-grade dysplasia. Twelve of 18 high-grade 
dysplasias contained cells that were marked with 
anti-FGF-1. IRSs ranged from 0 to 12 (mean IRS = 
4.5, moderate staining bordering on weak staining). 
Most reactive cases were moderately or strongly 
positive for FGF-1 (8/12). The remaining four cases 
were only weakly reactive. The mean high-grade 
dysplasia IRS of 4.5 is significantly different from the 
mean infiltrating adenocarcinoma IRS of 8 (p < 
0.05) (two-tailed t test) (Table II, Fig. 1). 
Low-grade dysplasia and intestinal metaplasia. 
Only rare, weak staining was identified in cases of 
low-grade dysplasia; three of 13 samples of low- 
grade dysplasia were positive for FGF-1, for an 
overall mean IRS of less than 1. Only six of 17 
metaplasias without dysplasia expressed any FGF-1 
at all, for an overall mean IRS of less than 1. The 
mean intestinal metaplasia nd low-grade dysplasia 
IRSs of less than 1 are significantly different from 
the mean high-grade dysplasia IRS of 4.5 (p < 
0.005) (two-tailed t test) (Table II, Fig. 1). 
Metaplasia-dysplasia-carcinoma sequence. Sixteen 
specimens contained at least three of the following 
lesions: intestinal metaplasia, low-grade dysplasia, 
high-grade dysplasia, or infiltrating adenocarci- 
noma. These cases were considered evaluable for 
FGF-I expression trends in the metaplasia-dyspla- 
sia-carcinoma sequence. Ten of 16 cases demon- 
strated a definite sequential increase in FGF-1 
immunoreactivity from intestinal metaplasia to dys- 
plasia and to carcinoma. Two additional cases 
showed a probable trend in increasing FGF-1 reac- 
tivity. Together, these 12 cases account for 75% of 
evaluable esophagectomy specimens. Two further 
cases failed to exhibit sequential increases in FGF-1 
staining. Finally, two cases were negative for FGF-1 
(Table III). 
Discussion 
Our data indicate that esophageal denocarcino- 
mas are largely FGF-1 reactive and that FGF-1 
expression correlates with the histologic grade of 
esophageal adenocarcinoma precursor lesions. 
Table IlL FGF-1 immunoreactive scores in 
esophagectomy specimens evaluable for the 
metaplasia-dysplasia-carcinoma sequence 
Increasing FGF-1 expression i the MDCS 
Case IM LGD HGD CA 
4 0 0 3 
17 0 2 9 12 
18 0 0 0 4 
21 0 0 0 4 
22 1 1 12 
23 0 2 12 
26 1 3 12 
27 0 6 9 
28 0 0 2 
29 0 0 12 
Probable trend 
5 1 0 0 12 
6 0 12 10 
No trend 
8 0 8 0 
24 1 12 4 
MDCS, Metaplasia-dysplasia-carcinoma sequence; IM, intestinal metapla- 
sia; LGD, low-grade dysplasia; HGD, high-grade dysplasia; CA, infiltrating 
adenocareinoma. 
Moderate to strong FGF-1 expression occurs in 
almost all esophageal denocarcinomas. This con- 
trasts with the weak to moderate FGF-1 expression 
in high-grade dysplasia and the almost negligible 
FGF-1 expression in low-grade dysplasia nd intes- 
tinal metaplasia. Furthermore, we show a trend 
toward increasing FGF-1 immunoreactivity within 
individual cases that contain lesions evaluable for 
the metaplasia-dysplasia-carcinoma sequence. Sub- 
jective interpretation of immunohistochemistry was 
minimized with the use of the German IRS, which 
has been shown to be equivalent o an image 
analysis-based quantitation of immunoreactivityY 
The trend toward increasing FGF-1 expression 
with the increasing histologic severity of Barrett's 
metaplasia and dysplasia llows us to make compar- 
isons with the progressive accumulation of tumor 
suppressor gene and oncogene abnormalities in 
similar lesions. A greater degree of p53 overexpres- 
sion, S-phase and DNA ploidy abnormalities, aswell 
as p53 mutations, have been reported in high-grade 
dysplasias and adenocarcinomas,  compared with 
intestinal metaplasias and low-grade dysplasias. 26-3° 
These data, in addition to ours, support he theory 
that high-grade dysplasia is an adenocarcinoma pre- 
cursor lesion. Although some studies have described 
similar abnormalities in intestinal metaplasia nd 
low-grade dysplasia, there is less molecular and 
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genetic data that links these lesions closely with 
adenocarcinoma. 26-2s Only three of our esophagec- 
tomy specimens contained both low-grade dysplasia 
and infiltrating adenocarc inoma without coexistent 
high-grade dysplasia, and all such cases demon-  
strated negligible FGF-1 expression in the low-grade 
dysplasia. Further investigation is needed to draw 
definite conclusions from these observations. 
The link between stromal reactions and FGF-1 is 
interesting iven the characteristic desmoplastic re- 
sponse of stroma infiltrated by adenocarcinoma. 
However,  we found rare cases in which nonneoplas- 
tic epithelium, including intestinal metaplastic epi- 
thelium, expressed FGF-1 in an eroded region or 
adjacent to an ulcer. We think that FGF-1 may be 
expressed by nonneoplastic epithelium, especially in 
sites of tissue injury; this has been reported in cases 
of chronic pancreatitis. 22 
Although FGF-1 expression is certainly conducive 
to tumor progression, it is probably not necessary, 
given our inability to demonstrate FGF-1 expression 
in three of the adenocarcinomas studied. Other 
investigations of FGF-1 expression have shown that 
the absence of FGF-1 mRNA correlates with failure 
to detect FGF-1 by immunohistochemical  meth- 
ods, 22 suggesting that FGF- l -negat ive cases in this 
study do not likely express FGF-1 mRNA.  We have 
excluded technical reasons for this negative FGF-1 
immunostaining because of appropriate FGF-1 ex- 
pression in the positive internal and external control 
specimens. Altered or mutated FGF-1, not recog- 
nized by the monoclonal  antibody used, may have 
given this result. Possibly, other fibroblast growth 
factors, such as FGF-2, contributed to tumor pro- 
gression. The FGF- l -negat ive adenocarc inoma of 
case 8 was associated with high-grade dysplasia that 
showed moderate FGF-1 reactivity. In rare cases, 
FGF-1 expression may be altered in the progression 
from high-grade dysplasia to infiltrating adenocarci- 
noma; we do not think these data indicate that 
high-grade dysplasia and infiltrating adenocarci- 
noma arise from different clones. 
In addition to its theoretic role in tumor progres- 
sion, FGF-1 immunohistochemistry may be useful in 
the diagnosis of Barrett 's esophagus and esophageal 
adenocarcinoma. Because of its preferential  expres- 
sion in high-grade dysplasia and infiltrating adeno- 
carcinoma, FGF-1 immunoreactivity may become 
useful as a means to distinguish low-grade from 
high-grade dysplasia, which is of clinical relevance. 
However,  our observation that low-grade lesions 
may express FGF-1 in ulcerated areas may compli- 
cate routine use. A prospective investigation to 
determine the biologic potential of FGF- l - react ive 
dysplasias would be informative. 
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Discuss ion 
Dr. Larry R. Kaiser (Philadelphia, Pa.). The study was 
strictly done with immunohistochemistry, andyou have 
shown previously in evaluating adenocarcinomas that you 
were able to measure message. Did you in any of these 
look for message or have you looked at fresh specimens 
for DNA? I think that the limitations of immunohisto- 
chemistry are numerous. It is a qualitative study. It 
depends on who is grading these specimens. Did a blinded 
observer look at your immunohistochemistry? How many 
observers looked at it? The measurements can vary ac- 
cording to the controls. They can vary according to the 
conditions under which the immunohistochemistry is 
done. Did you go beyond just the qualitative measure- 
ments ince you have demonstrated the capability to do it 
on adenocareinomas? 
Dr. Soslow. To get around the problem of qualitative 
observation and scoring of the immunohistochemistry, we 
purposely used this adaptation of the German IRS, which 
was shown to be equivalent to an image analysis-based 
quantitation of immunohistochemical re ctivity. 
